statistiche ricercatore

AGENO, WALTER

Distribuzione geografica

Continente	#
NA - Nord America	49.567
EU - Europa	24.108
AS - Asia	13.619
SA - Sud America	1.930
AF - Africa	170
Continente sconosciuto - Info sul continente non disponibili	56
OC - Oceania	25
Totale	89.475

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	49.173
IT - Italia	11.650
SG - Singapore	4.620
UA - Ucraina	4.090
TR - Turchia	2.831
HK - Hong Kong	1.897
SE - Svezia	1.849
CN - Cina	1.794
DE - Germania	1.786
VN - Vietnam	1.762
BR - Brasile	1.648
IE - Irlanda	1.233
GB - Regno Unito	960
RU - Federazione Russa	843
FI - Finlandia	821
FR - Francia	307
IN - India	201
CA - Canada	195
MX - Messico	155
BD - Bangladesh	117
AT - Austria	105
AR - Argentina	99
JP - Giappone	90
PL - Polonia	85
NL - Olanda	84
ES - Italia	80
ZA - Sudafrica	70
IQ - Iraq	60
EU - Europa	53
EC - Ecuador	49
BE - Belgio	44
CZ - Repubblica Ceca	34
CO - Colombia	31
LT - Lituania	29
VE - Venezuela	27
SA - Arabia Saudita	26
MA - Marocco	25
UZ - Uzbekistan	25
ID - Indonesia	24
CL - Cile	23
PK - Pakistan	23
AE - Emirati Arabi Uniti	21
PY - Paraguay	21
AU - Australia	19
CH - Svizzera	18
DZ - Algeria	16
KE - Kenya	15
UY - Uruguay	15
JO - Giordania	14
MY - Malesia	14
PT - Portogallo	13
EG - Egitto	12
RO - Romania	11
GR - Grecia	9
IL - Israele	9
IR - Iran	9
BO - Bolivia	8
TN - Tunisia	8
TT - Trinidad e Tobago	8
CR - Costa Rica	7
DK - Danimarca	7
KR - Corea	7
LB - Libano	7
MK - Macedonia	7
PE - Perù	7
PS - Palestinian Territory	7
TW - Taiwan	7
BG - Bulgaria	6
HU - Ungheria	6
KZ - Kazakistan	6
NP - Nepal	6
OM - Oman	6
AL - Albania	5
AZ - Azerbaigian	5
CI - Costa d'Avorio	5
JM - Giamaica	5
NZ - Nuova Zelanda	5
RS - Serbia	5
BA - Bosnia-Erzegovina	4
ET - Etiopia	4
GE - Georgia	4
LK - Sri Lanka	4
NG - Nigeria	4
BB - Barbados	3
BN - Brunei Darussalam	3
BS - Bahamas	3
BY - Bielorussia	3
DO - Repubblica Dominicana	3
GT - Guatemala	3
HN - Honduras	3
HR - Croazia	3
KW - Kuwait	3
PA - Panama	3
PH - Filippine	3
SN - Senegal	3
AM - Armenia	2
AO - Angola	2
EE - Estonia	2
KH - Cambogia	2
LI - Liechtenstein	2
Totale	89.440

Salva come PNG Salva come JPEG

Città	#
Milan	8.497
Fairfield	7.198
Woodbridge	4.799
Ashburn	4.127
Houston	3.555
Jacksonville	3.302
Seattle	2.802
Wilmington	2.630
Singapore	2.517
Cambridge	2.459
Ann Arbor	2.425
Chandler	2.236
Hong Kong	1.887
Dallas	1.539
Izmir	1.395
Princeton	1.350
Dublin	1.224
Dearborn	961
Boardman	830
Dong Ket	683
Nyköping	664
Rome	628
The Dalles	536
Beijing	507
Chicago	423
San Diego	398
Los Angeles	334
San Mateo	308
New York	271
Ogden	261
London	254
Como	190
Santa Clara	172
São Paulo	167
Washington	164
Munich	153
Ho Chi Minh City	144
Düsseldorf	139
Hefei	126
Redmond	122
Nanjing	98
Kocaeli	88
Nuremberg	88
Mexico City	84
Tokyo	83
Kunming	82
Verona	81
Hanoi	77
Norwalk	75
Helsinki	74
Warsaw	72
Phoenix	69
Montreal	68
Council Bluffs	65
Salt Lake City	64
Guangzhou	62
Brooklyn	61
Buffalo	60
Stockholm	59
Nanchang	57
San Francisco	55
Turku	55
Chennai	52
Jinan	52
Rio de Janeiro	52
Boston	50
Columbus	49
Orem	49
Tampa	48
Toronto	48
Frankfurt am Main	47
Atlanta	46
Denver	46
Belo Horizonte	45
Johannesburg	42
Vienna	42
Kilburn	39
San Jose	39
Amsterdam	38
Falls Church	38
Brussels	37
Elk Grove Village	37
Philadelphia	36
Besana In Brianza	33
Fuzhou	30
Manchester	30
Shanghai	30
Brno	28
Curitiba	28
Poplar	28
Prescot	27
Redwood City	26
Zhengzhou	26
Chiswick	25
Detroit	25
Berlin	23
Querétaro	23
Brasília	22
Miami	22
Mumbai	22
Totale	65.334

Salva come PNG Salva come JPEG

Nome	#
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: a Delphi analysis of experts	391
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery	295
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes	291
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study	280
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study	275
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis	261
A case report and literature review of portal vein thrombosis associated with Cytomegalovirus infection in immunocompetent patients	252
Abdominal obesity and the risk of recurrent deep vein thrombosis	249
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature	247
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review	246
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry	232
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism	232
Risk of recurrence of unusual site venous thromboembolism	231
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal	231
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment	231
Breadth of complications of long-term oral anticoagulant care	229
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature	228
ABO blood group and vascular disease: an update	228
Management of recurrent venous thromboembolism in cancer patients	228
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry.	226
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.	223
Optimal treatment duration of venous thrombosis	221
Prevention and treatment of venous thromboembolism	219
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients	215
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome	214
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis.	213
A new era for venous thromboembolism prevention in medical inpatients	213
Venous ischemic syndromes	213
Exaggerated initial response to warfarin following heart valve replacement	212
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism	212
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	211
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.	211
Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy	211
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data	209
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program.	208
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study	208
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry	208
Patient selection for thromboprophylaxis in medical inpatients	207
A comparative study using thrombin generation and three different INR methods in patients on Vitamin K antagonist treatment	207
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial	205
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty	204
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice	204
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis	202
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review	201
A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy.	200
Warfarin interactions with antibiotics in the ambulatory care setting	200
Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants	200
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study	199
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis	198
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: A multicenter cohort study	198
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism	197
Venous thromboembolism: “…an ounce of prevention is worth a pound of cure”	197
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis	196
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study	195
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study	195
Venous and arterial thrombosis in patients with HIV infection	194
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?	194
Oral rivaroxaban for symptomatic venous thromboembolism	193
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry.	193
A survey of thromboprophylaxis management in patients with major trauma.	193
Management of incidental splanchnic vein thrombosis in cancer patients	193
Applying EBM in clinical practice	192
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis	192
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients	191
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications	191
Abdominal obesity and the risk of recurrent deep vein thrombosis.	190
Venous thromboembolism: Past, present and future	190
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study	190
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation	189
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study	188
Treating patients with cancer and acute venous thromboembolism	188
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature	188
Atypical case of Acute Coronary Syndrome due to Coronary-Pulmonary Steal Syndrome secondary to Pulmonary Embolism.	187
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation	187
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians	187
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy	187
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree?	186
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study	185
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature: a reply to a rebuttal	184
Duration of anticoagulation after venous thromboembolism in real world clinical practice	184
Anticoagulation After Stroke in Patients With Atrial Fibrillation: To Bridge or Not With Low-Molecular-Weight Heparin?	184
Statins and secondary prevention of ischemic and hemorrhagic stroke	183
Acute myeloid leukemia with associated translocation t(15;17) and 11q23/MLL abnormality	183
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study	183
Guidance for the management of venous thrombosis in unusual sites	183
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis	183
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study	183
Update on the diagnosis and management of pulmonary embolism	183
Direct oral anticoagulants in rare venous thrombosis	182
Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice.	181
24-hour blood pressare profile and left ventricular anatomy and function in untreated hypertensives with and without microalbuminuria	181
Managing challenging patients with venous thromboembolism: A practical, case-based approach	181
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE	180
Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation	180
Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study	180
When and how to use antidotes for the reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH	179
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism: An analysis of the randomised, double-blind HOKUSAI VTE trial	178
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature	178
Statins for acute ischemic stroke	178
Antidotes for the direct oral anticoagulants: What news?	178
Totale	20.666

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	396.534
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	396.534

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	8.021	0	0	0	0	0	1.396	543	1.226	1.503	803	953	1.597
2021/2022	6.828	757	872	355	182	402	376	337	375	386	1.267	644	875
2022/2023	6.740	824	258	431	650	510	1.571	19	787	1.024	268	191	207
2023/2024	13.559	2.152	2.188	2.195	2.612	2.767	824	95	147	391	79	37	72
2024/2025	9.742	69	75	1.781	238	230	684	403	654	1.099	820	967	2.722
2025/2026	10.024	1.428	1.409	1.478	2.721	1.762	1.226	0	0	0	0	0	0
Totale													90.367